ArticleBMC neurology2026
Case report: anti-NMDAR encephalitis with cerebellar ataxia as the initial manifestation.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAmong autoimmune encephalitis (AE), anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is the most common type. In patients with anti-NMDAR encephalitis, psychiatric and cognitive symptoms were often observed as the initial manifestations, whereas cerebellar ataxia was rarely reported. CASE PRESENTATION: We report the case of a 22-year-old male patient who initially presented with cerebellar ataxia and was eventually diagnosed with anti-NMDAR encephalitis on the basis of positive results for anti-NMDAR antibodies in the cerebrospinal fluid. After combined therapy with intravenous immunoglobulin, methylprednisolone, and rituximab and subsequent rehabilitation, the patient’s symptoms were gradually alleviated.
conclusionsThis case highlights the atypical presentation of anti-NMDAR encephalitis with cerebellar ataxia as the initial symptom, which is rare. Granule cell dysfunction, due to the wide distribution of GluN1 subunits, may disrupt the signaling to Purkinje cells, resulting in ataxia. Early recognition and treatment with immunotherapy, followed by rehabilitation, are crucial for improving patient outcomes, especially in cases with atypical presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.